Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.
Advertisement
All: Please discuss the recent data on PFS and DOR for BRAF-MEK inhibitors combinations.
Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.
UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.